Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ANS BIOTECH - AUVERGNE<br />
NEUROSCIENCES<br />
Biopôle Clermont Limagne<br />
63360 SAINT BEAUzIRE - FRANCE<br />
Phone: +33 4 73 17 82 36<br />
Fax: +33 4 73 17 82 34<br />
Email: francois.caussade@ans-biotech.com<br />
Web site: www.ans-biotech.com<br />
Contact: François CAUSSADE<br />
ANS Biotech, a preclinical CRO dedic<strong>at</strong>ed to pain pharmacology, supports drug<br />
discovery and development efforts of companies involved in human and animal health,<br />
food and nutrition, by providing them with:<br />
• clinically relevant in vivo models for successful R&D of innov<strong>at</strong>ive analgesics,<br />
especially in the field of inflamm<strong>at</strong>ory pain, neurop<strong>at</strong>hic pain and visceral pain<br />
• customized scientific studies meeting drug discovery and development<br />
objectives<br />
• consulting activities.<br />
ARIANA<br />
PHARMACEUTICALS<br />
28 rue du Docteur Finlay<br />
75015 PARIS - FRANCE<br />
Phone: +33 01 44 37 17 00<br />
Fax: +33 01 44 37 17 01<br />
Email: info@arianapharma.com<br />
Web site: www.arianapharma.com<br />
Contact: Mohammad AFSHAR<br />
Ariana, a spin-off of the Institut Pasteur, is a leading decision support and d<strong>at</strong>a<br />
mining company, focused on transforming d<strong>at</strong>a into inform<strong>at</strong>ion to acceler<strong>at</strong>e the<br />
discovery and development of biomarkers and pharmaceutical drugs. Ariana has<br />
developed KEM ® (Knowledge Extraction Management), a proprietary decision support<br />
technology for rapid analysis of multi-parametric / multi-objective d<strong>at</strong>a. KEM is<br />
routinely applied to the identific<strong>at</strong>ion of Biomarkers, optimiz<strong>at</strong>ion in drug discovery,<br />
analysis of clinical d<strong>at</strong>a and early signal detection in drug safety.<br />
29
Change language